Diabetes technology & therapeutics最新文献_第9页

GLP-1 Receptor Agonist Therapy in Cystic Fibrosis-Related Diabetes: A Case Report. GLP-1 受体激动剂治疗囊性纤维化相关糖尿病：病例报告。

IF 5.7 2区医学

Diabetes technology & therapeutics Pub Date : 2025-02-01 Epub Date: 2024-10-03 DOI: 10.1089/dia.2024.0367

Gida Ayada, Sagit Zolotov, Raya Cohen, Tal Lavi, Muhammad Abdul-Ghani, Naim Shehadeh, Afif Nakhleh

引用次数: 0

Automated Insulin Delivery Effects During Driving Among Older Adults with Type 1 Diabetes in a Randomized Trial. 一项随机试验中老年1型糖尿病患者驾驶过程中自动胰岛素输送效果

IF 5.7 2区医学

Diabetes technology & therapeutics Pub Date : 2025-02-01 Epub Date: 2024-12-02 DOI: 10.1089/dia.2024.0303

Steven Trawley, Hye Jin Kwon, Sara Vogrin, Peter G Colman, Spiros Fourlanos, Melissa H Lee, Richard J MacIsaac, David N O'Neal, Niamh A O'Regan, Vijaya Sundararajan, Glenn M Ward, Sybil A McAuley

{"title":"Automated Insulin Delivery Effects During Driving Among Older Adults with Type 1 Diabetes in a Randomized Trial.","authors":"Steven Trawley, Hye Jin Kwon, Sara Vogrin, Peter G Colman, Spiros Fourlanos, Melissa H Lee, Richard J MacIsaac, David N O'Neal, Niamh A O'Regan, Vijaya Sundararajan, Glenn M Ward, Sybil A McAuley","doi":"10.1089/dia.2024.0303","DOIUrl":"10.1089/dia.2024.0303","url":null,"abstract":"Dysglycemia among drivers with type 1 diabetes (T1D) is associated with impaired driving performance, and glucose levels \"above 5 to drive\" are often recommended for insulin-treated drivers. Evidence for diabetes treatments that support euglycemia while driving is minimal, particularly for older drivers. In this randomized, crossover trial involving adults aged ≥60 years with T1D, we used continuous glucose monitoring (CGM) during driving to compare the first-generation closed-loop automated insulin delivery (AID) versus a sensor-augmented pump therapy. There were 1894 trips undertaken by 8 drivers (median age 68 years [IQR: 64-70]). During AID versus sensor-augmented pump, time in range >5.0-10.0 mmol/L was greater (100% [0-100] vs. 81% [0-100]; P = 0.033) and fewer trips had any CGM >16.7 mmol/L (3.5% vs. 6.4%; P = 0.006). Three percent of all trips included CGM <3.9 mmol/L, with no between-stage difference (3.0% vs. 3.5%; P = 0.52). System alerts occurred in 10% of all trips, with no between-stage difference (9% vs. 11%; P = 0.078). First-generation AID reduces hyperglycemic driving among older drivers with T1D, without increasing hypoglycemia. Developing dedicated \"driving-mode\" settings could prioritize safety while minimizing distraction. Trial Registration: ACTRN12619000515190.","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"134-138"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insulin Pump Use and Diabetic Ketoacidosis Risk in Type 1 Diabetes: Secular Trends over Four Decades. 1 型糖尿病患者使用胰岛素泵与糖尿病酮症酸中毒风险：四十年来的长期趋势

IF 5.7 2区医学

Diabetes technology & therapeutics Pub Date : 2025-02-01 Epub Date: 2024-10-10 DOI: 10.1089/dia.2024.0272

Dalton R Budhram, Priya Bapat, Abdulmohsen Bakhsh, Mohammad I Abuabat, Natasha J Verhoeff, Doug Mumford, Wajeeha Cheema, Andrej Orszag, Akshay Jain, David Z I Cherney, Michael Fralick, Bader N Alamri, Alanna Weisman, Leif Erik Lovblom, Bruce A Perkins

{"title":"Insulin Pump Use and Diabetic Ketoacidosis Risk in Type 1 Diabetes: Secular Trends over Four Decades.","authors":"Dalton R Budhram, Priya Bapat, Abdulmohsen Bakhsh, Mohammad I Abuabat, Natasha J Verhoeff, Doug Mumford, Wajeeha Cheema, Andrej Orszag, Akshay Jain, David Z I Cherney, Michael Fralick, Bader N Alamri, Alanna Weisman, Leif Erik Lovblom, Bruce A Perkins","doi":"10.1089/dia.2024.0272","DOIUrl":"10.1089/dia.2024.0272","url":null,"abstract":"Introduction: Continuous subcutaneous insulin infusion (CSII) in type 1 diabetes has been regarded as a major diabetic ketoacidosis (DKA) risk factor. We aimed to determine secular trends in risk since CSII implementation in the 1980s. Research Design and Methods: We assessed the relationship between time-varying CSII use and DKA events from 1983 to 2017 and by each decade in the 1441 Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study participants using crude and adjusted Cox proportional hazards models. Results: Time-varying CSII exposure was associated with significantly higher DKA risk in the 1980s (adjusted hazard ratio [HR] 5.81; 95% confidence interval [CI] 3.28-10.29; P < 0.001), but in the 2010s, this risk was not significantly elevated (adjusted HR 1.24; 95% CI 0.73-2.12; P = 0.43). Conclusions: DKA risk associated with CSII in type 1 diabetes has declined substantially since the 1980s such that the remaining risk in the past decade appears to be of low magnitude.","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"139-143"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of an Automated Priming Bolus for Improving Prandial Glucose Control in Full Closed Loop Delivery. 评估全闭环给药中用于改善餐前血糖控制的自动启动给药。

IF 5.7 2区医学

Diabetes technology & therapeutics Pub Date : 2025-02-01 Epub Date: 2024-11-06 DOI: 10.1089/dia.2024.0315

Marcela Moscoso-Vasquez, Patricio Colmegna, Charlotte Barnett, Morgan Fuller, Chaitanya L K Koravi, Sue A Brown, Mark D DeBoer, Marc D Breton

{"title":"Evaluation of an Automated Priming Bolus for Improving Prandial Glucose Control in Full Closed Loop Delivery.","authors":"Marcela Moscoso-Vasquez, Patricio Colmegna, Charlotte Barnett, Morgan Fuller, Chaitanya L K Koravi, Sue A Brown, Mark D DeBoer, Marc D Breton","doi":"10.1089/dia.2024.0315","DOIUrl":"10.1089/dia.2024.0315","url":null,"abstract":"Background: Automated insulin delivery (AID) is widely available to people with type 1 diabetes (T1D), providing superior glycemic control versus traditional methods. The next generation of AID devices focus on minimizing user/device interactions, especially around meals (\"full closed loop,\" [FCL]). Our goal was to assess the postprandial glycemic impact of the bolus priming system (BPS), an algorithm delivering fixed insulin doses based on the likelihood of a meal having occurred, in conjunction with UVA's latest AID. Method: Eleven adults with T1D participated in a supervised randomized-crossover trial assessing glycemic control during two 24-h sessions with identical meals and activity-with and without BPS. On the day in-between study sessions, participants underwent food and activity challenges to test BPS safety and robustness. Continuous glucose monitor (CGM) outcomes and total insulin doses were assessed overall and following meals with potential for BPS to dose additional insulin (CGM >90 mg/dL for 1 h prior). Results: Daytime CGM outcomes were similar with and without BPS: time-in-range (TIR) 70-180 mg/dL 70.6% [62.2-76.5] versus 65.7% [58.6%-80.6%]; time-below-range <70 mg/dL 0% [0-2.1] versus 0% [0-1.3]; respectively. Insulin delivery during 3 h postprandial was indistinguishable 33.5 U [26.4-47.0] versus 35.7 U [28.7-44.9]. Among 43 out of 66 meals with potential to trigger BPS (24/19 BPS/no-BPS), postprandial incremental area-under-the-curve (iAUC) was lower for BPS versus no-BPS (2530 ± 1934 versus 3228 ± 2029, P = 0.047), but CGM outcomes were inconclusive: 4-h-TIR 51.2% [19.8-83.3] versus 40.2% [20.8-56.3] (P = 0.24). There were no severe adverse events. Conclusion: While there was no difference in TIR, when BPS was active an improved postprandial AUC in FCL was obtained via earlier insulin injection.","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"93-100"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study. 评估 365 天植入式 Eversense 连续血糖监测系统的准确性和安全性：ENHANCE 研究。

IF 5.7 2区医学

Diabetes technology & therapeutics Pub Date : 2025-01-27 DOI: 10.1089/dia.2024.0592

Timothy S Bailey, David R Liljenquist, Douglas S Denham, Ronald L Brazg, Sorin Ioacara, James Masciotti, Samanwoy Ghosh-Dastidar, Katherine S Tweden, Francine R Kaufman

{"title":"Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study.","authors":"Timothy S Bailey, David R Liljenquist, Douglas S Denham, Ronald L Brazg, Sorin Ioacara, James Masciotti, Samanwoy Ghosh-Dastidar, Katherine S Tweden, Francine R Kaufman","doi":"10.1089/dia.2024.0592","DOIUrl":"https://doi.org/10.1089/dia.2024.0592","url":null,"abstract":"The implanted Eversense Continuous Glucose Monitoring (CGM) System transitioned from 90- to 180- to 365-day durations marketed today. This report summarizes the 365-day clinical study. ENHANCE was a prospective, multicenter study evaluating the accuracy and safety of the Eversense 365 CGM system through 1 year in adults with diabetes. Accuracy and adverse events (AEs) were assessed during 14 in-clinic visits comparing CGM and Yellow Springs Instrument reference glucose measurements, including during hyperglycemia and hypoglycemia challenges. In total, 110 participants were implanted with the Eversense 365 CGM System. The overall mean absolute relative difference was 8.8% with primarily one calibration per week. The confirmed alert detection rate at 70 mg/dL was 96.6%, and at 180 mg/dL, it was 97.9%. Ninety percent of the sensors survived 365 days. Interoperable CGM special controls were met. No related serious AEs were reported. The Eversense 365 CGM was shown to be safe and accurate through 1 year with primarily one calibration per week.","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ranting in 2025: It's Not the Same Rant. 2025年的咆哮：不一样的咆哮。

IF 5.7 2区医学

Diabetes technology & therapeutics Pub Date : 2025-01-17 DOI: 10.1089/dia.2025.0005

Irl B Hirsch

引用次数: 0

Glycemic Control Across the Menstrual Cycle in Women with Type 1 Diabetes Using the MiniMed 780G Advanced Hybrid Closed-Loop System: The 780MENS Prospective Study. 使用最小化780G高级混合闭环系统控制1型糖尿病女性月经周期血糖：780MENS前瞻性研究

IF 5.7 2区医学

Diabetes technology & therapeutics Pub Date : 2025-01-16 DOI: 10.1089/dia.2024.0522

Gabriela Monroy, María José Picón-César, Jorge García-Alemán, Francisco J Tinahones, José Ignacio Martínez-Montoro

{"title":"Glycemic Control Across the Menstrual Cycle in Women with Type 1 Diabetes Using the MiniMed 780G Advanced Hybrid Closed-Loop System: The 780MENS Prospective Study.","authors":"Gabriela Monroy, María José Picón-César, Jorge García-Alemán, Francisco J Tinahones, José Ignacio Martínez-Montoro","doi":"10.1089/dia.2024.0522","DOIUrl":"https://doi.org/10.1089/dia.2024.0522","url":null,"abstract":"Objective: To evaluate whether the MiniMed™ 780G advanced hybrid closed-loop (AHCL) system maintains similar glycemic control across two different phases of the menstrual cycle in women with type 1 diabetes (T1D) and to analyze the system's performance in these situations. Methods: Continuous glucose monitoring (CGM) and insulin delivery metrics from 12 participants with T1D using the MiniMed™ 780G AHCL were analyzed throughout 3 prospectively recorded, consecutive menstrual cycles (36 cycles in total). Mixed models were used to compare the different variables between the early follicular phase and late luteal phase. Results: A higher average glucose was found throughout the late luteal phase compared with the early follicular phase (139.5 [133.5, 145.2] vs. 131.5 [126.8, 140.2] mg/dl, respectively, P = 0.002), together with an increase in total daily insulin dose (37.2 ± 11.9 vs. 33.6 ± 12.2 IU, P < 0.001). However, similar values between phases were observed for most of the remaining CGM metrics, including time in range (83.0 [76.0, 87.5] vs. 85.0 [79.8, 89.0] %, P = 0.101). Conclusion: Our results suggest that differences in glycemic control may be found across the menstrual cycle in women with T1D using the MiniMed™ 780G AHCL. Although higher average glucose levels may be expected in the late luteal phase, the deterioration of glycemic control during this phase may be mild with the MiniMed™ 780G AHCL, given the similarities for most of the CGM metrics with respect to the early follicular phase.","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Accuracy of Continuous Glucose Monitoring in Adults with Type 1 Diabetes Admitted to Hospital: A Real-World Multicenter Observational Study. 住院成人1型糖尿病患者连续血糖监测的准确性：一项真实世界多中心观察性研究

IF 5.7 2区医学

Diabetes technology & therapeutics Pub Date : 2025-01-13 DOI: 10.1089/dia.2024.0604

Ray Wang, Mervyn Kyi, Brintha Krishnamoorthi, Jason Tjahyadi, Ailie Connell, Cherie Chiang, Debra Renouf, Rahul Barmanray, Spiros Fourlanos

{"title":"Accuracy of Continuous Glucose Monitoring in Adults with Type 1 Diabetes Admitted to Hospital: A Real-World Multicenter Observational Study.","authors":"Ray Wang, Mervyn Kyi, Brintha Krishnamoorthi, Jason Tjahyadi, Ailie Connell, Cherie Chiang, Debra Renouf, Rahul Barmanray, Spiros Fourlanos","doi":"10.1089/dia.2024.0604","DOIUrl":"https://doi.org/10.1089/dia.2024.0604","url":null,"abstract":"Introduction: Continuous glucose monitoring (CGM) use in people with type 1 diabetes (T1D) is revolutionizing management. Use of CGM in hospital is poised to transform care, however routine use is not currently recommended due to lack of accuracy validation in acute care, including in people with T1D. We aimed to determine real-world CGM accuracy in hospitalized adults with T1D. Materials and Methods: In this multicenter retrospective observational study, we compared CGM interstitial fluid glucose with reference blood glucose (capillary/whole-blood point-of-care [POC], blood gas [GAS]) in adults with T1D requiring multiday admissions during 2020-2023 across three health services in Australia. Patients requiring dialysis or admitted under pediatric/obstetric/palliative care/psychiatry units were excluded. CGM accuracy was assessed by comparison with time-matched (±5 min) reference glucose measures, utilizing median absolute relative difference (ARD), mean ARD (MARD), and consensus error grid (CEG) analysis. Results: In total, 2,199 CGM-reference glucose pairs from 214 admissions (146 patients) were assessed. Overall, mean (SD) ARD was 12.8% (13.1) and median (IQR) ARD was 9.4% (3.7-17.7). MARD for CGM-POC pairs was 12.3%; MARD for CGM-GAS pairs was 14.3%. In CEG analysis, 99.3% of glucose pairs were within zones A/B. Accuracy was lower in critical care compared with noncritical care wards (MARD 16.1% vs. 12.0%, P < 0.001). Conclusions: In this real-world multicenter study, CGM glucose agreed well with reference blood glucose, suggesting modern CGM devices could be safely and effectively used in hospitalized adults with T1D. Further prospective studies of CGM accuracy with newer generation devices across different scenarios will further elucidate inpatient CGM accuracy and safety.","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Continuous Glucose Monitoring Systems in Noninsulin-Treated People with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (doi: 10.1089/dia.2023.0390). 修正：连续血糖监测系统在非胰岛素治疗的2型糖尿病患者：随机对照试验的系统评价和荟萃分析（doi: 10.1089/dia.2023.0390）。

IF 5.7 2区医学

Diabetes technology & therapeutics Pub Date : 2025-01-08 DOI: 10.1089/dia.2023.0390.correx

引用次数: 0

Safety of Options to "Boost" (Enhancing Insulin Infusion Rates) and "Ease-Off" (Reducing Insulin Infusion Rates) in CamAPS FX Hybrid Closed-Loop System: A Real-World Analysis. CamAPS FX 混合闭环系统中 "提升"（提高胰岛素输注率）和 "轻松关闭"（降低胰岛素输注率）选项的安全性：真实世界分析。

IF 5.7 2区医学

Diabetes technology & therapeutics Pub Date : 2025-01-01 Epub Date: 2024-09-09 DOI: 10.1089/dia.2024.0298

Chloë Royston, Simon Bergford, Peter Calhoun, Judy Sibayan, Yue Ruan, Charlotte Boughton, Malgorzata E Wilinska, Roman Hovorka

引用次数: 0